Clinical Trial Search

Primary: Number of Participants With Adverse Events (AEs), Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Deaths, and TEAEs Leading to Discontinuation…

Primary: Audiometry - Pure Tone Average Done Over 1000, 2000 and 4000 Hertz (HZ) — -0.3; 0.71; -0.8; 0.3 decibels

Primary: Complete or Partial Objective Tumor Response — 3 Participants

Primary: Antimicrobial Activity of C16G2 — -0.2; -0.04; 0.005; 0.15 CFU/mL

Primary: Antimicrobial Activity of C16G2 — -0.49; 0.23; -0.44; -0.31 CFU/mL

Primary: Number of Subjects With Treatment-Emergent Adverse Events (TEAEs) and Dose Limiting Toxicities (DLTs) — 4; 5; 19; 36 Participants

Primary: Change in Hypoxic Burden (HB) Log Transformed - Log10HB[(%*Min)/h] — -0.40; -0.21; 0.18 difference in log10HB[(%*min)/h]

Primary: Number of Participants With All Adverse Events (AEs), Medically Attended Adverse Events (MAAEs), Serious Adverse Events (SAEs), and Significant New Medical Conditions…

Primary: Treatment-specific Baseline Estimated Glomerular Filtration Rate Based on Creatinine (eGFRcr) — 32.7; 34.9 mL/min/1.73m^2

Primary: Difference in 24 Hour Ambulatory Systolic Blood Pressure — 7.7; 12.5 mm Hg

Primary: Number of Primary Prostate Lesions Detected on Early Dynamic 68Ga-PSMA-11 PET/CT Imaging — 24 lesions

Primary: Comparison of the Rate of Treatment Success at 18 Months (After Treatment Initiation) Between Arms B and C — 217; 121; 117; 5 Participants

Primary: Phase I: Maximum Tolerated Dose — 500 mg/m^2

Primary: Adverse Event — 0; 1 adverse events

Primary: Ketamine (AUC) — 28.46 mcg*min/mL